Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) and Q&A Session Transcript

Jan 10, 2022 / 03:30PM GMT
Release Date Price: $76.39 (-16.79%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analyst here at JPMorgan. I'm joined by Priyanka Grover, Malcolm Kuno and Caleb Smith from the team. Our next presenting company is Sarepta, and presenting on behalf of the company, we have CEO, Doug Ingram. I want to remind all the attendees to use the ask-a-question feature in the portal. If you have a question, I'm happy to ask it on your behalf.

With that, Doug, take it away.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you, Anupam, and good morning, everyone, and thank you all for joining us today. I'll wait for the slides to pop up. There we go.

Sarepta, hopefully, as you know, is 1 of the world's leading biotechs in the use of precision genetic medicine to treat life-ending rare diseases. And we have the strategy, we have the science, and frankly, we have the execution-focused tenacity to become what I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot